CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PRECISION BIOSCIENCES INC

DTIL
$185MMicro Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for DTIL. That does not mean none is planned.

Get an email about DTIL's next catalysts

Track PRECISION BIOSCIENCES (DTIL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Catalyst Timeline

0 upcoming, 3 past

No catalysts found.

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)BiotechnologyπŸ‡ΊπŸ‡ΈNorth AmericaDURHAM192 employees

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

Website
Drug Pipeline

Frequently asked questions

What is in PRECISION BIOSCIENCES INC's drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in PRECISION BIOSCIENCES INC's (DTIL) pipeline across Phase 2. Its lead program is NEO-201 in combination with pembrolizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is PRECISION BIOSCIENCES INC's next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for PRECISION BIOSCIENCES INC (DTIL) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track DTIL biotech catalysts?β†’

Add DTIL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PRECISION BIOSCIENCES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply